Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Dermatology, Ommelander Ziekenhuis Groningen, Groningen, The Netherlands.
Clin Otolaryngol. 2018 Oct;43(5):1321-1327. doi: 10.1111/coa.13176. Epub 2018 Jul 19.
Mohs micrographic surgery (MMS) is the treatment of choice for high-risk primary basal cell carcinoma (BCC) and recurrent BCC of the head and neck, showing fewer recurrences compared with surgical excision (SE). The objectives of this study were to determine the recurrence rate of head and neck BCC after MMS and to develop a prediction model with significant risk factors for recurrence.
A retrospective study of patient records.
All BCCs treated with MMS between 1 January 1995 and 1 July 2013 at the University Medical Center Groningen (UMCG) were selected retrospectively. Recorded parameters were patient characteristics, tumour size, tumour location, histopathological subtype, previous treatment, the number of stages until microscopic clearance, defect size, adverse events, follow-up time and recurrence after MMS.
The study covered 1021 MMS operations conducted on primary BCCs (57.4%), residual BCCs (25.6%) and recurrent BCCs (17.0%). The median follow-up time was 54.0 months (ranging from 1 to 221 months). The 5-year cumulative probability of recurrence was 3.3%: 2.6% for primary BCCs, 5.4% for residual BCCs and 2.9% for recurrent BCCs. An aggressive histopathological subtype, residual BCCs and recurrent BCCs were significant risk factors for predicting a higher risk of recurrence after MMS.
This large-scale retrospective study showed low recurrence rates after MMS for primary and recurrent BCCs. Residual BCCs treated with MMS had relatively higher recurrence rates. The risk of recurrence for MMS-treated residual aggressive BCCs was more than four times higher than that for primary non-aggressive BCCs.
Mohs 显微外科手术(MMS)是治疗高危原发性基底细胞癌(BCC)和头颈部复发性 BCC 的首选方法,与手术切除(SE)相比,复发率较低。本研究的目的是确定 MMS 治疗后头颈部 BCC 的复发率,并建立一个具有显著复发风险因素的预测模型。
回顾性患者记录研究。
回顾性选择 1995 年 1 月 1 日至 2013 年 7 月 1 日期间在格罗宁根大学医学中心(UMCG)接受 MMS 治疗的所有 BCC。记录的参数包括患者特征、肿瘤大小、肿瘤位置、组织病理学亚型、既往治疗、达到显微镜下完全清除的阶段数、缺损大小、不良事件、随访时间和 MMS 后的复发情况。
本研究涵盖了 1021 例原发性 BCC(57.4%)、残余 BCC(25.6%)和复发性 BCC(17.0%)的 MMS 手术。中位随访时间为 54.0 个月(1 至 221 个月)。5 年累积复发率为 3.3%:原发性 BCC 为 2.6%,残余 BCC 为 5.4%,复发性 BCC 为 2.9%。侵袭性组织病理学亚型、残余 BCC 和复发性 BCC 是预测 MMS 后复发风险较高的显著危险因素。
这项大规模回顾性研究显示,MMS 治疗原发性和复发性 BCC 的复发率较低。MMS 治疗的残余 BCC 复发率相对较高。MMS 治疗的复发性侵袭性 BCC 的复发风险是原发性非侵袭性 BCC 的四倍多。